Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.83 USD
+0.04 (4.44%)
Updated Aug 29, 2024 04:00 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
SGMO 0.83 +0.04(4.44%)
Will SGMO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
Other News for SGMO
Biotech Alert: Searches spiking for these stocks today
3 Penny Stocks to Watch Now, 8/8/24
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Sangamo Biosciences: Hold Rating Amid Financial Challenges and Clinical Progress